XML 28 R17.htm IDEA: XBRL DOCUMENT v3.8.0.1
Intangible Assets
 3 Months Ended
Mar. 31, 2018
Intangible Assets, Net (Excluding Goodwill) [Abstract]  
Intangible Assets
Intangible assets

The following table summarizes the Company's intangible assets:
(In millions)
Currently marketed products
 
IPR&D
 
Other intangible assets
 
Total
March 31, 2018
 
 
 
 
 
 
 
Gross acquired intangible assets
$
32,274.8

 
$
5,114.8

 
$
835.9

 
$
38,225.5

Accumulated amortization
(5,000.6
)
 
—

 
(360.6
)
 
(5,361.2
)
Intangible assets, net
$
27,274.2

 
$
5,114.8

 
$
475.3

 
$
32,864.3

 
 
 
 
 
 
 
 
December 31, 2017
 

 
 

 
 

 
 

Gross acquired intangible assets
$
31,973.5

 
$
5,113.9

 
$
835.9

 
$
37,923.3

Accumulated amortization
(4,549.2
)
 
—

 
(328.0
)
 
(4,877.2
)
Intangible assets, net
$
27,424.3


$
5,113.9


$
507.9


$
33,046.1



Other intangible assets are comprised primarily of royalty rights and other contract rights associated with Baxalta, Dyax Corp. (Dyax), and NPS Pharmaceuticals Inc. 

Activities in the net book value of intangible assets for the three months ended March 31, 2018 and 2017 are as follows: 
(In millions)
2018
 
2017
As of January 1,
$
33,046.1

 
$
34,697.5

Changes
34.9

 
(1,685.0
)
Amortization charged
(484.0
)
 
(364.0
)
Foreign currency translation
267.3

 
185.6

As of March 31,
$
32,864.3

 
$
32,834.1

 

Changes included in the three months ended March 31, 2017 related to measurement period adjustments of the acquisition of Baxalta.